Axa
ACHN

Axa’s Achillion Pharmaceuticals ACHN Stock Holding History

Axa’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-562,773
Closed -$1.67M – 1406
2019
Q1 		$1.67M Sell
562,773
-599,854
-52% -$1.47M 0.01% 879
2018
Q4 		$1.85M Hold
1,162,627
– – 0.01% 844
2018
Q3 		$4.28M Hold
1,162,627
– – 0.02% 715
2018
Q2 		$3.29M Buy
1,162,627
+14,793
+1% +$50.4K 0.01% 742
2018
Q1 		$4.26M Sell
1,147,834
-11,721
-1% -$38.4K 0.02% 695
2017
Q4 		$3.34M Buy
1,159,555
+378,199
+48% +$1.37M 0.01% 752
2017
Q3 		$3.51M Sell
781,356
-10,850
-1% -$48.2K 0.02% 713
2017
Q2 		$3.64M Sell
792,206
-29,207
-4% -$117K 0.02% 672
2017
Q1 		$3.46M Sell
821,413
-25,198
-3% -$105K 0.02% 669
2016
Q4 		$3.5M Buy
846,611
+16,091
+2% +$85.5K 0.02% 646
2016
Q3 		$6.73M Sell
830,520
-102,264
-11% -$870K 0.03% 510
2016
Q2 		$7.28M Sell
932,784
-38,173
-4% -$327K 0.03% 475
2016
Q1 		$7.5M Sell
970,957
-15,686
-2% -$115K 0.03% 456
2015
Q4 		$10.6M Sell
986,643
-30,563
-3% -$278K 0.05% 364
2015
Q3 		$7.03M Buy
1,017,206
+262,204
+35% +$2.14M 0.03% 471
2015
Q2 		$6.69M Hold
755,002
– – 0.03% 511
2015
Q1 		$7.44M Buy
755,002
+357,230
+90% +$4.46M 0.03% 472
2014
Q4 		$4.87M Sell
397,772
-66,857
-14% -$816K 0.02% 561
2014
Q3 		$4.64M Buy
+464,629
New +$4.31M 0.02% 559
2013
Q3 		– Sell
-117,541
Closed -$961K – 1357
2013
Q2 		$961K Buy
+117,541
New +$897K 0.01% 849

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Axa's ACHN Position: Q2 2019 in Review

Axa sold out of Achillion Pharmaceuticals (ACHN) in Q2 2019, closing a stake of 562,773 shares — an estimated $1.67M sold.

Axa first reported a position in ACHN in Q2 2013 and held it in 20 quarters. The position peaked at $10.6M in Q4 2015. 114 funds tracked by Wall St. Rank hold ACHN as of Q2 2019.

  • Axa reported no remaining Achillion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Axa sold 562,773 Achillion Pharmaceuticals shares in Q2 2019, an estimated $1.67M.
  • Axa first reported a position in Achillion Pharmaceuticals in Q2 2013 and held it in 20 quarters.
  • Axa's Achillion Pharmaceuticals position peaked at $10.6M in Q4 2015.
  • 114 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2019.

Based on Axa's 13F filing for Q2 2019, filed 13 Aug 2019.